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ABSTRACT
Anaplastic thyroid cancers and radioiodine resistant thyroid cancer are posing 
a major treat since surgery combined with Iodine131 therapy is ineffective on them. 
Small-molecule inhibitors are presenting a new hope for patients, but often lead to 
drug resistance in many cancers. Based on the major mutations found in thyroid 
cancer, we propose the combination of a MEK inhibitor and a Pi3’-kinase inhibitor 
in pre-clinical models. We used human thyroid cancer cell lines and genetically 
engineered double mutant BRAFV600E PIK3CAH1047R mice to evaluate the effect of both 
inhibitors separately or in combination in terms of proliferation and signaling in vitro; 
tumor burden, histology, cell death induction and tumor markers expression in vivo. 
The combination of MEK and Pi’3-kinase inhibition shows a synergistic effect in term 
of proliferation and apoptosis induction through Survivin down-regulation in vitro. 
We show for the first time the effects of the combination of a MEK inhibitor and 
Pi3’-kinase inhibitor in a genetically engineered mouse model of aggressively lethal 
thyroid cancer. In fine, the two drugs cooperate to promote tumor shrinkage by 
inducing a proliferation arrest and an elevation of apoptosis in vivo. Moreover, a 
phenotypic reversion is also observed with a partial restoration of normal thyroid 
marker transcription, and thyroid cancer marker expression reduction.
In conclusion, combination therapy of MEK and Pi3’-kinase inhibition synergizes 
to target double mutant thyroid cancer in vitro and in vivo. This multidrug approach 
could readily be translated into clinical practice and bring new perspectives for the 
treatment of incurable thyroid carcinoma.
INTRODUCTION
Thyroid cancer is the most common endocrine 
cancer. Its incidence has been rapidly increasing over 
the last decades but with a stable related morbidity 
rate [1]. Better detection of small tumors, thanks to the 
increased use of ultrasound and also histopathological 
over diagnosis, explains a part the rising incidence [2, 3]. 
The other part may be explained by increasing exposure to 
high levels of radiation including from radiation treatment 
to the head and neck, and/or fallout from nuclear power 
plant accidents or weapons testing [4].
About 62,500 new cases of thyroid cancer and more 
than 1,900 related deaths are estimated for 2015 in the 
United States according to the American Cancer Society, 
with a prevalence in women 3 times as high as in men 
[5]. Nevertheless, morbidity remains low compared to 
most other cancers since the more common subtypes of 
thyroid cancers have an excellent prognosis. Differentiated 
thyroid cancers including papillary (PTC) and follicular 
(FTC) thyroid cancers represent 90% of all thyroid cancers 
[6]. With 80% of cases, PTC is the most prevalent type. 
It responds very well to therapy consisting of surgery 
combined with therapeutic radioiodine (131I). However, 
patients with more advanced thyroid malignancies present 
the greatest challenge in the management of thyroid 
cancer. Anaplastic thyroid carcinoma (ATC) although rare, 
causes almost 50% of thyroid cancer related deaths [7]. 
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This undifferentiated subtype is associated with a very poor 
prognosis and considered as one of the most aggressive 
cancers in humans with a 5-months median survival 
[8]. ATC is suspected to arise from well-differentiated 
thyroid carcinomas like PTC by further progression/
dedifferentiation or to arise via poorly differentiated 
thyroid carcinomas (PDTC) [9, 10].
ATC presents as a diffuse invasion of structures in 
the neck such as trachea, esophagus, blood vessels and 
nerves, making surgery difficult to perform. Ultimately, 
this results in dyspnea and suffocation, which is the main 
cause of death in patients [11]. Nevertheless, metastasis is 
still observed in 10-20% of ATC cases, predominantly in 
the lung and bones [12].
BRAF is part of the Mitogen-activated protein 
kinase (MAPK) pathway leading to MAPK/ERK kinase 
(MEK) and Extracellular signal–regulated kinase (ERK) 
phosphorylation. It is commonly activated by somatic 
mutations in human cancer [13]. Detected in 8% of all 
cancers, BRAF mutations are common in melanoma and 
thyroid cancer with respective frequencies of 60% and 
40%. The point mutation A1799T, coding for the V600E 
transversion, accounts for 90% of BRAF mutations. 
It is the most common mutation found in PTC (45% of 
patients), however, BRAF alone as a prognostic factor 
is controversial [14]. Data from sequencing of PDTC 
and ATC suggest, that the progression from well-
differentiated thyroid cancers to ATC happens as a result 
of the cooperation between multiple acquired alterations 
such as mutations in CTNNB1 (Human β-catenin gene), 
PIK3CA (Phosphatidylinositol 3-kinase catalytic subunit), 
TP53 (Transformation related protein 53) and PTEN 
(Phosphatase and tensin homolog). Furthermore, copy 
number and epigenetic changes involving oncogenes have 
been described in this context [15]. 
Facing human cohort recruitment difficulties, animal 
models recapitulating the key genetic aspects of ATC are 
needed as a substitute. Currently, investigations are based 
on large retrospective cohort studies with a paucity of 
prospective randomized trials. Recently, significant efforts 
have been made in the direction of developing murine 
preclinical platforms allowing, on one hand, a better 
understanding of crucial events in the disease initiation 
and progression and, on the other hand, evaluation of 
rational targeted therapies. The role of the most common 
mutation BRAFV600E in PTC initiation has been shown in 
several independent mouse models. First, thyroid-specific 
transgenic overexpression of BRAFV600E, induces goiter 
and invasive PTC with tall-cell features, which later 
transition to poorly differentiated carcinomas [16]. Later, 
a mouse model using thyroid-specific recombination to 
mimick the point mutation event observed in patients, 
demonstrated that BRAFV600E expression was sufficient to 
drive PTC formation [17].
Furthermore, several mouse models associating 
BRAF mutations to other oncogenic mutations have been 
described [18]. Deletion or dominant negative mutation of 
TP53 leads to progression from PTC to ATC [19]. Another 
model using PIK3CAH1047R and BRAFV600E expression in 
the thyroid showed that the combination cooperates to 
promote tumor progression to ATC, characterized by local 
invasion and subsequent death of the mice by suffocation 
[20], resembling very closely the human disease.
Thyroid tumors carrying BRAFV600E mutations are 
assumed to be exquisitely dependent on the oncoprotein 
activity for viability. Thus, pharmacological inhibition is 
associated with tumor regression and a partial restoration 
of the differentiated phenotype [17]. However, mono-
therapies targeting one component of the MAPK pathway 
in human patients are only transiently effective in some 
cancers such as melanoma, since resistance arises 
frequently after few months [21]. This resistance is due 
to reactivation of the ERK signaling pathway via various 
mechanisms [22, 23].
We hypothesize that targeting both MAPK and 
Phosphoinositide 3′-kinase (Pi3′-kinase) pathways by 
inhibiting the mutated enzymes that drive the development 
of the disease or their downstream targets MEK would 
have clinically measurable beneficial effect. To address 
this question, we started by studying the effect of drugs 
targeting the two pathways in human ATC cell lines. We 
looked at eventual cooperation and possible molecular 
mechanisms driving it. We used a mouse model of 
aggressive PTC that progresses to ATC (thyrocyte-specific 
expression of BRAFV600E and PIK3CAH1047R [20]) to 
evaluate the combination effects of MEK and PI3′-kinase 
inhibition in a pre-clinical context. The tumor burden 
measured by ultrasound was used as a read-out, along 
with the evaluation of the expression of clinical markers 
of thyroid cancer and the transcription of normal thyroid 
markers in tumor tissue from treated mice. 
RESULTS
MEK inhibition synergizes with Piʹ3-kinase 
inhibition in ATC cell lines 
Since cancer is driven by multiple mutational 
events, multidrug approaches are now becoming standard 
to tackle tumors. Moreover, most mono-therapies are 
showing mitigated results and emergence of resistance 
mechanisms with time. We wanted to assess if targeting 
MEK downstream of BRAF in combination with a Pi3′-
kinase inhibitor induces stronger proliferation reduction 
than any drug alone in human ATC cell lines. Three 
cell lines with BRAFV600E mutations were selected. 
The SW1736 cell line has no other mutations reported. 
However, OCUT-2 cells have an additional PIK3CAH1047R 
mutation and 8505c cells have both TP53 and CDKN2A 
(Cyclin Dependent Kinase Inhibitor 2) deletions. 
We used PD-325901, which is a potent and selective 
MEK1/2 inhibitor that has reached phase II clinical trials 
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for advanced non-small lung cancer, as a single agent [24]. 
For Pi3′-kinase inhibition, we used GDC-0941, currently 
studied in phase Ib/II clinical trials for solid tumors [25].
To test the nature of the collaboration between the 
two drugs, we performed a synergy test by incubating cells 
with a range of concentrations from 0.016 fold of IG50 to 10 
fold of IG50 obtained by 5-fold serial dilutions. The specific 
Half-maximal inhibitory growth concentrations (IG50) of 
PD-325901 and GDC-0941 used to calculate synergy, and 
previously determined for each cell line experimentally, 
were respectively around 10 nM and 200 nM in both 
OCUT-2 and SW1736 cell lines. In 8505c cell line, the 
IG50 concentrations were 20 nM and 300 nM. In 8505c 
and OCUT-2 cells, a greater inhibition of proliferation was 
obtained with the combination, as seen by the left shift of 
the combination curve compared to the single treatment 
curves. This effect was less pronounced in SW1736 cells 
(Figure 1A). The constant concentration ratio approach 
(See Material and Methods) allowed us to calculate the 
combination index from the obtained proliferation data 
based on the method of Chou and Talalay [26].
The strongest synergistic effect was obtained in 
OCUT-2 cell lines followed by 8505c. In SW1736 The 
combination index was ranged from 0.8 to 0.9 over the 
concentrations tested. Even though 1.0 is the mathematical 
threshold, 0.85 is considered a more significant threshold 
since, statistically, the combination index cannot be 
considered to show any effect deviating from the additivity 
between 0.85 and 1.0 [27]. We can say then that in this cell 
line we have, in the range of concentrations used, an effect 
between additive and moderately synergistic (Figure 1B).
To understand the mechanism underlying the 
inhibition, we investigated the effect of the drugs on cell 
cycling. PD-325901 alone or in combination with GDC-
0941 induced a G1 cycle arrest in SW1736 and 8505c cell 
lines. However, in OCUT-2, a significant effect was only 
observed for the combination (Figure 1C). Altogether 
this moderate additional cytostatic effect of the drug 
combination could not explain the synergy in terms of 
reduction in cell number. Therefore, we hypothesized 
that induction of cell death could explain the difference 
observed. We then performed an apoptosis assay by flow 
cytometry using annexinV and Propidium Iodide (PI). 
Only the OCUT-2 cell line already showed increased 
apoptosis (double positive annexinV and PI cells) when 
treated with the combination for 24 h (Figure 2A). 
However, after 48 h of combination treatment, all three 
cell lines (Figure 2B and Supplementary Figure 1) had 
elevated double positive annexinV/PI cells (late apoptosis) 
and annexinV positive cells (early apoptosis). The most 
Figure 1: Drug combination synergistically inhibits thyroid cancer cell proliferation. (A) Differential response to single 
and combination treatment with MEK and PI3′-kinase inhibitors: Human anaplastic thyroid cancer cells were treated with increasing 
concentrations of single drugs PD-325901, GDC-0941 or the combination at a constant ratio for about 3 doubling population times. All drug 
concentrations were normalized to IG50 equivalents of single agents (see Materials and Methods). Optical Density values were normalized 
to the untreated. All the measurements were done in triplicate and the mean was represented with SEM. The constant ratio approach allows 
figuring out obvious synergistic effect between drugs and calculating the combination index. (B) Combination index (CI) as a function of 
Fraction affected (Fa): Combination index curves were calculated using Compusyn Software 2.0 based on Chou and Talalay method. The 
horizontal red line indicates the synergistic effect threshold. (C) Cell cycle analysis on cells treated with single drug or the combination: 
Cell cycle analysis was performed on 8505c, OCUT-2 and SW1736 treated for 24 h with PD-325901 at 100 nM and/or GDC-0941 at 1 µM. 
Bars represent percentage of cells in each cell cycle stage as the mean of triplicates from independent experiments with the calculated 
Standard Deviation.
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Figure 2: Drug combination synergistically induces apoptosis in anaplastic thyroid cancer cell lines. (A) Flow cytometry 
analysis of OCUT-2 cells treated with 100 nM of PD-325901, 1 µM of GDC-0941 or the combination for 24 h stained with FITC annexinV 
and PI. Apoptosis was detected by FITC annexinV binding to the cells. Quadrant Lower Left, FITC annexinV(−) PI(−) represents living 
cells. Quadrant Lower Right, PI(+) represents cells undergoing necrosis. Quadrant Upper Right, FITC annexinV(+) PI(+) represents cells 
in the late apoptosis and undergoing secondary necrosis. Quadrant Upper Left, FITC annexinV (+) PI(−) are cells in early  apoptosis. The 
histograms represent the quantifications of intact cells, early apoptotic cells, late apoptotic cells and necrotic cells in the 3 cell lines after 24 
h treatments as the mean of triplicate from 3 independent experiments. Error bars represent SEM. (B) Flow cytometry analysis of OCUT-
2 cells treated with 100 nM of PD-325901, 1 µM of GDC-0941 or the combination for 48 h stained with FITC annexinV and PI. The 
histograms represent the quantifications of intact cells, early apoptotic cells, late apoptotic cells and necrotic cells in the 3 cell lines after 
48  h treatments as the mean of triplicate from 3 independent experiments. Error bars represent SEM.
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remarkable observation was the significant decrease of 
intact cells with drug combinations in all three cell lines 
after 48 h.
To further investigate the observed apoptosis, 
we performed western blot analysis. ERK1/2 and AKT 
phosphorylation were assessed first to demonstrate the 
drug efficiency. ERK1/2 phosphorylation ratio (p-ERK1/2 
normalized to total ERK) was strongly decreased in all 
cell lines when treated with PD-325901 alone or in 
combination with GDC-0941. Similarly, GDC-0941 
induced a strong reduction of AKT phosphorylation ratio 
(Figure 3). Ribosomal S6 phosphorylation was affected 
by both treatments and the combination resulted in further 
de-phosphorylation of S6 showing a collaborative effect of 
the two drugs at the level of this signaling node.
Cell death was also investigated by detection of 
cleaved caspase 3 (CC3). In all three cell lines, CC3 
was mainly driven by PD-325901 treatment, but still 
showed a further elevation upon addition of GDC-0941. 
We additionally tested modulators of caspase activity 
like Survivin: there we could detect a down regulation of 
Survivin in whole protein lysates that was also found in 
the drug combination. This conjunction of CC3 elevation 
combined with down regulation of Survivin could very 
likely explain the increased cell death that was observed 
with a time shift of 24 to 48 h. Apoptotic cell death was 
assessed here by monitoring DNA fragmentation with 
gamma-H2AX that was found increased under drug 
treatments in both whole cell lysates and nuclear extracts 
(Figure 3) in the three cell lines. We also tested alternative 
mechanisms of apoptosis like X-chromosome-linked 
inhibitor of apoptosis protein (XIAP) down regulation or 
induction of the apoptosis inducing factor (AIF) but these 
did not show any differences in expression (Figure 3).
BRAFV600E and PIK3CAH1047R tumors regressed 
under MEK inhibitor treatment and further if 
combined with Pi3′-kinase inhibitor
To test if PD-325901 and GDC-0941 would 
also cooperate in vivo, we used a previously described 
mouse model of thyroid cancer [20]. In this model, the 
endogenous expression of BRAFV600E and PIK3CAH1047R 
can be induced by tamoxifen specifically in thyrocytes at 
30 days of age. After tamoxifen injection, mice rapidly 
develop PTC that progresses to ATC and death of the 
mouse within 3 to 6 months after the drug-induced 
mutational induction [20]. Treatment of mice with drugs 
was started 2 months after tumor induction and ultrasound 
measurements were performed weekly to assess the tumor 
burden (Figure 4A–4B). Untreated mice display a steadily 
increasing tumor burden reaching 220% over the time 
of the experiment. GDC-0941 treated mice presented a 
20% tumor burden reduction at 6 weeks of treatment but 
Figure 3: The combination PD-325901/GDC-0941 inhibits MAPK and Pi3′-kinase pathways and leads to caspase 
dependent cell death enhanced by Survivin downregulation. Western blot showing the expression of component of signaling 
pathways and proteins involved in apoptosis caspase dependent and caspase independent in the 3 ATC cell lines treated for 24 h with single 
treatments or the combination PD-325901/GDC-0941. The quadrants in red correspond to the nuclear fraction and in black to the total extract.
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regained their starting size after 9 weeks. Interestingly, 
PD-325901 treated mice presented a 40% tumor burden 
reduction after 6 weeks of treatment and remained stable 
for the rest of the experiment. Strikingly, the combination 
treated animals had a more pronounced response with a 
60% tumor burden reduction after 7 weeks (Figure 4A).
After 9 weeks of treatment, we seemed to have achieved 
a maximum stable response for the combo-treated animals. 
Therefore, three mice from each group were dissected and 
thyroids were processed for histological analysis. Untreated 
mice showed an expected histology with PTC areas, tall cell 
morphology and phenotypic progression to ATC in some 
areas. Interestingly, PD-325901 treated mice showed a clear 
improvement in histology with some almost normal follicles 
and smaller PTC areas. GDC-0941 did not induce a beneficial 
effect at the histological level. Finally, mice treated with the 
combination, although resulting in smaller sections, seemed 
to have a similar histological presentation to PD-325901 alone 
treated animals (Figure 4C). 
In terms of signaling, ERK and AKT phosphorylation 
ratios were assessed by western blot after 9 weeks of 
treatment to demonstrate the efficacy of the drug regimen. 
PD-325901 alone or in combination was able to induce 
a strong dephosphorylation of ERK1/2. However, GDC-
0941 induced only a small non-significant decrease in 
terms of AKT phosphorylation. In tumors from PD-
325901 treated animals there was a tendency to elevated 
AKT phosphorylation, that became significant in the 
combination treatment (Figure 5A–5B). The lack of effect 
of GDC-0941 on AKT-phosphorylation was unexpected. 
Therefore, we tested the drug on mice over a shorter period 
of time. Another group of mice was treated with only one 
dose of GDC-0941 by oral gavage then sacrificed 4 hours 
later. In this setting, western blots showed a much stronger 
reduction of AKT phosphorylation (-80%) (Figure 5C–5D) 
showing that the drug was efficiently inhibiting Pi3′-
kinase, even if the effect on the read-out pAKT does not 
seem to last under a chronic treatment.
Drug removal induces immediate regrowth of all 
tumors
To test if the treatment was curative we performed 
tumor burden measurement after drug release in two mice 
remaining from the PD-325901 and GDC-0941 treatment 
groups and one mouse remaining from the combo-treated 
group (after week 9). From the ultrasound data acquired 
in this configuration we could clearly conclude that in 
all treated mice living tumor cells were remaining and 
capable of re-growing suggesting that the treatments were 
not curative (Figure 6A).
Looking at the histology of re-growth, untreated 
mice displayed features of progression with large areas 
of ATC. GDC-0941 treated mice although presenting the 
biggest tumors, look mostly like regular PTC and did not 
seem to have progressed to ATC. Thyroids in mice treated 
with PD-325901 or the combination no longer showed 
the histological improvement seen after treatment and 
presented with an aggressive phenotype (Figure 6B).
BRAFV600E and PIK3CAH1047R tumors regressed 
under MEK and Pi3′-kinase inhibition by reducing 
cell proliferation and increasing cell death
In order to understand the mechanisms driving the 
tumor regression, we performed immunofluorescence 
staining for Ki67, CC3 and DNA fragmentation (Terminal 
deoxynucleotidyl transferase dUTP nick end labeling 
or TUNEL) on thyroid sections of the 9 weeks treated 
mice. The proliferation index was significantly reduced 
in tumors from PD-325901 treated animals or in the 
combination treated group compared to the control, 
but not significantly in the GDC-0941 treated group 
(Figure 7A). Concerning CC3, we could see an increase in 
PD-325901 and GDC-0941 treated mice, but the combination 
resulted the highest score even if that was not statistically 
significant (Figure 7B). We performed TUNEL staining to 
monitor DNA laddering, the main hallmark of apoptosis 
driven cellular death, and we could find a significantly 
elevated positive staining in tumors from the PD-325901 and 
the combination treated animals (Figure 7C).
To confirm the phenotype reversion found in 
PD-325901 treated thyroids, we performed staining 
for the tumor markers Cytokeratin 19 (CK19) and 
Galectin-3 (Gal-3), that are clinically used markers of 
thyroid cancer. While controls and GDC-0941 treated 
samples showed clear positive staining, PD-325901 and 
combination treated animals showed drastically reduced 
positivity for CK19 and very low positivity for Galectin-3 
(Figure 8A). In fact, Galectin-3 positive cells observed in 
PD-325901 and combination treated samples are immune 
cells (e.g. macrophages) trapped in the cystic areas. This 
reversion was also tested by measuring thyroid specific 
markers by qPCR. PD-325901 induces the re-expression 
of all normal thyroid markers tested: Sodium Iodide 
Symporter (Nis), transcription factor Paired Box 8 (Pax8), 
Thyroid Stimulating Hormone Receptor (Tsh-r), Thyroid 
Peroxidase (Tpo) and Thyroglobulin (Tg). All of these 
genes, but Pax8, showed elevation of the transcription 
with MEK inhibition treatment, while GDC-0941 showed 
almost no alteration. Combination treatment showed 
elevations but not higher than MEK inhibition alone 
(Figure 8B).
DISCUSSION
The management of ATC with multimodality treatment 
has so far failed to improve survival in patients. The lack 
of randomized studies prevents clinicians from being 
conclusive about the benefits of the available treatments 
including surgery. To improve the outcome, rationally 
targeted therapies are needed. Well-differentiated thyroid 
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Figure 4: The combination is more beneficial after 9 weeks of treatment in terms of tumor burden reduction compared 
to PD alone and shows histology improvement. (A) Thyroid tumor burden during treatment measured by ultrasound imaging 
expressed in percentage of the starting tumor burden. The mean of each treated group was calculated with SEM. 2-way ANOVA test with 
Tukey as post hoc test were used for multiple comparison (B) Representative pictures of ultrasound pictures at the end of the treatment 
(9 weeks). (C) Hematoxylin and Eosin stainings at 5× and 40× magnification of representative thyroid tissues after 9 weeks of treatments 
of mice by oral gavage with Vehicle, PD-325901 at 5 mg/kg, GDC-0941 at 50 mg/kg and combination. 
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carcinomas are treated effectively by surgical resection and 
radioiodine therapy but there are limitations in using this 
strategy in ATC and radioiodine resistant PTC. The local 
invasiveness characterizing the undifferentiated type (ATC) 
is making it almost inoperable because of the presence of 
vital vessels and nerves. Understanding the key genetic 
events promoting the dedifferentiation and consequently 
progression and the maintenance of aggressive kinds of 
thyroid cancers is therefore crucial for the development of 
new effective treatments.
Currently, more and more efforts are focusing in 
the development of combination treatments targeting 
more than one target and/or pathway. This trend in cancer 
research is based on the fact that mono-chemotherapy is 
often associated with resistance, recurrence and sometimes 
worsening of the disease.
Synergy in combining anticancer drugs has to be 
uncovered empirically taking advantage of pre-clinical 
models like cell culture and genetically engineered mice. 
Previously published work has shown that BRAFV600E 
and PIK3CAH1047R mutations collaborate to promote 
rapid PTC formation and eventual ATC progression [20]. 
Moreover, these mutations are frequently found in ATC 
[28] with 25% for BRAFV600E and 15% for PIK3CAH1047R. 
In addition, PIK3CA is also found frequently amplified in 
ATC [29]. Targeting both the RAF→MEK→ERK and the 
Pi3′-kinase→AKT→mTOR pathways is therefore a good 
rational to tackle aggressive forms of thyroid cancer.
The synergistic effect observed when targeting both 
pathways in two ATC cell lines demonstrates that the two 
pathways are needed to drive proliferation (Figure 1A–1B). 
Interestingly, synergy was stronger in OCUT-2 cell line, 
the only cell line harboring both the BRAFV600E and the 
PIK3CAH1047R mutations emphasizing the oncogene 
addiction effect. Nonetheless, the synergistic effect was 
observed in 8505c and an additive effect close to synergy 
was found in SW1736. As the later have no known 
mutations in PIK3CA, this suggest that these cell lines 
still require “wildtype” Pi3′-kinase activity to maintain 
proliferation. A similar synergistic effect was observed in 
thyroid cancer cell lines using RAF inhibitors (RAF265 
and ZSTK474) with a Pi3′-kinase inhibitor (SB590885) 
in two PTC cell lines and in 8505c [30] or using a MEK 
inhibitor (AZD6244) with GDC-0941 on OCUT-1 cells 
and other PTC cell lines [31]. This shows that a variety 
of thyroid cancer cell lines are responding synergistically 
to drugs targeting the same (or similar) signaling nodes, 
thus supporting our presented data. Interestingly, it was 
Figure 5: PD and GDC drugs are hitting their target in vivo based on the decreased phosphorylation of ERK and AKT. 
(A) Western blot showing the expression of pERK1/2, pAKT, pERK, panAKT in the tumors of control and treated mice for 9 weeks (B) 
Quantification of ratio pERK/totERK and pAKT/panAKT after 9 weeks of treatment. Means are represented with SEM and One-way Anova 
test with Dunnett as post hoc were used to assess statistical significance (C) Western blot showing the expression of pERK1/2, pAKT, pERK, 
panAKT in the tumor of control and treated mice with 1 shot GDC-0941 at 50 mg/kg by oral gavage. (D) Quantification of ratio pERK/
totERK and pAKT/panAKT after short treatment with GDC-0941 (1× 50 mg/kg). the statistical significance was evaluated using a T test.
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Figure 6: Tumors regrow after treatment release with different rate and seem to lose the histological improvement 
observed under treatment. (A) Tumor burden during treatment (9 weeks) and regrowth after treatment removal up to 20 weeks 
measured on remaining mice. (B) Hematoxylin and Eosin staining at 5× and 40× magnification of representative thyroids tissues after 
treatment removal with a control mouse euthanized at week 11 after reaching endpoint. PD-325901, GDC-0941 and combination treated 
mice were sacrificed at week 20 (11 weeks after drug release).
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also previously shown that blocking Pi3′-kinase can help 
overcome the resistance of some thyroid cancer cell lines 
to Tumor Necrosis Factor-Alpha-Related Apoptosis-
Inducing Ligand (TRAIL) signaling (Lexatumumab), 
confirming the crucial role of Pi3′-kinase involvement in 
thyroid cancer cells’ drugs response [32]. 
Since cell cycle analysis could not explain the 
observed synergy: G1 arrest with marginal further effect 
when combined (Figure 1C–1D); we aimed at investigating 
drug-induced cell death mechanisms in the three ATC 
cell lines. To that end we evaluated cell death induction 
by performing annexinV/PI staining. An apoptotic 
effect of the drugs in the three cell lines could be seen 
48h after treatment and, interestingly in these cases, the 
proportion of early or late apoptosis or necrosis was quite 
variable between the 3 cell lines, but ultimately the drug 
Figure 7: Drug treatments induce a decrease in proliferation and increased cell death. Representative immunofluorescence 
images of isolated thyroid tissues and corresponding quantification. The tissues were isolated after 9 weeks of treatment. (A) Blue: DAPI 
and Green: Ki67. The graph shows the percentage of Ki67 positive cells. (B) Green: CC3. The graph displays the count of CC3 apoptotic 
bodies normalized to nuclei number. (C) Green: TUNEL. The graph depicts the count of TUNEL positive apoptotic bodies normalized to 
the number of nuclei. All quantifications were performed on whole tumor sections using Quant Center software from 3DHISTECH. The 
mean of different measurements (thyroid lobes) are represented for each treatment group with SEM. One-way ANOVA test with Tukey as 
post hoc test were used to calculate statistical significance.
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Figure 8: MEK inhibition alone or combined with Pi3′-kinase inhibition leads to a reduction in tumoral markers and 
an up-regulation of normal phenotype markers. (A) Representative immunofluorescence images at 4×, 20× and 40× magnifications 
of isolated thyroid tissues from mouse treated 9 weeks with drugs. Blue: DAPI, Red: CK19, Green: Galectin-3. (B) mRNA expression 
levels of proteins involved in the normal function of the thyroid normalized to the untreated expressed in fold induction. Actin was used as 
house keeping gene and all measurements were done in triplicate and represented as the mean with SEM. One-way ANOVA test and Tukey 
test were used for multiple comparison.
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combination induced a superior effect, in terms of reducing 
the number of intact cells in the three cell lines than any 
drug alone (Figure 2B and Supplementary Figure 1).
In order to understand this drug-driven apoptosis 
induction, we investigated the effect of the treatments on 
cell signaling by western blotting. CC3 was moderately 
increased 24 h after treatment with MEK inhibitor but 
more when combined with the Pi3′-kinase inhibitor. 
Because the delay in apoptosis induction suggested that 
another mechanism was involved, we then looked for 
alternative cell death mechanisms. AIF does not involve 
caspases (its translocation into the nucleus leads to DNA 
fragmentation). However, none of our different treatments 
had any influence in both total and nuclear AIF levels 
suggesting no involvement of this mechanism. Gamma-
H2AX, a marker of DNA damage which is a late event 
shared by all cell death mechanisms [33], increased with 
MEK inhibitor alone and further with the combination. 
We then investigated mechanisms involved in the 
regulation of CC3 activity. We found that Survivin, a 
member of inhibitor of apoptosis protein family (IAP) that 
sequestrates caspases and prevents the activation of the 
cascade responsible for apoptosis [34], was downregulated 
with drug treatments (Figure 3). This effect relying on 
protein turnover could explain the delayed apoptosis seen 
in cells (Figure 2).
This drug combination effect has never been tried in 
genetically engineered mouse model of thyroid cancer. We 
wanted to translate this synergistic effect observed in cells 
into a highly clinically relevant model in vivo. In a very 
similar fashion, both drugs showed a significant effect on 
tumor burden, but the combination showed an even more 
pronounced effect, that was statistically significant after 
7 weeks of treatment (Figure 4A). Tumor growth was 
stabilized by GDC-0941 treatment, unlike the controls 
that kept on growing. This is a very interesting result 
showing that PIK3CA is not only important for the tumor 
in the initial phase [20] but that tumors still rely on its 
activity even a few months after induction. In addition, 
while untreated mice had several more aggressive regions 
looking like ATC at the end of the experiment (Figure 
4C) GDC-0941 treated thyroids showed mainly PTC-like 
lesions. These observations also confirm the importance 
of the PIK3CAH1047R mutation for ATC progression, as 
published previously [20]. The observed reduction in the 
tumor burden after PD-325901 treatment (Figure 4A), 
was due to a cell proliferation arrest (Figure 7A). This 
effect was potentiated by the combination with GDC-
0941, with a more profound tumor burden reduction 
(60% for the combination versus 40% for PD-325901 
alone) that could be explained by an apoptosis induction 
in addition to the PD-325901-dependent proliferation 
arrest (Figure 7A–7C), since the proliferation index was 
similarly affected. As shown by histology (Figure 4C), we 
were able to achieve a partial tumor remission in the time 
period considered (9 weeks) which is already a remarkable 
result considering the aggressive nature of the disease 
we were dealing with. Nevertheless, the remaining cells 
were still viable and resumed growth after drug removal 
(Figure 6). This implies that mutant cells could be tamed 
by MEK inhibition, but recover their aggressive behavior 
after drug removal. We think that MEK inhibition mainly 
pushes cells to re-differentiate. Then cells failing to 
repair their high genomic damage undergo apoptosis 
under the treatment pressure. Consequently, the high-
grade tumor areas get killed and replaced by cells which 
succeeded to differentiate and/or the already resistant well 
differentiated tumor cells. The concomitant occurrence of 
re-differentiation and apoptosis was suggested by some 
studies however others propose that apoptosis is occurring 
later on [35, 36].
In terms of drug effect and pathways, we were able 
to show that MEK inhibition could maintain ERK1/2 
phosphorylation levels to a practically undetectable 
level over the whole period of drug dosage (Figure 5A). 
We think that ERK1/2 inactivation promotes the re-
differentiation of cells into functional thyrocytes. This 
is supported by the fact that thyroid cancer markers 
Cytokeratin-19 and Galectin-3 detection are strongly 
reduced upon MEK inhibition (Figure 6A). In addition, 
qPCR showed that normal thyroid markers that are 
usually lost in advanced thyroid cancers [37] are partially 
restored by the drug (Figure 8B), possibly rendering the 
tumor susceptible to radioactive iodine again. This is 
consistent with what has been previously published by 
the group of Prof. James Fagin in a PTC model [38]. 
Nevertheless, this is the first time that this effect is shown 
in a PTC/ATC mouse model where therapeutic options are 
extremely limited. In addition, we also show that while 
GDC-0941 induces a further decrease in tumor burden, 
it does not induce an additional beneficial effect in terms 
of thyroid marker expression, meaning that Pi3′-kinase 
does not play such a differentiation-driver role as ERK 
in the context of thyroid cancer. This was consistent with 
a recently published paper showing that complete ERK 
inhibition with a MEK inhibitor maximizes the responses 
of BRAFV600E thyroid cancers to radioiodine by inducing 
sustained re-differentiation [39].
Unlike MEK inhibition, Pi3′-kinase inhibition could 
not maintain low AKT phosphorylation levels over time, 
meaning that another mechanism comes to compensate this. 
Still, the drug presents a strong effect in terms of tumor 
burden showing that Pi3′-kinase effect cannot be only 
reduced to AKT phosphorylation. A similar observation 
has been shown in another study by our group (Roelli et al, 
Manuscript in preparation). This uncoupling of Pi3′-kinase 
inhibition effect and AKT phosphorylation suggesting 
AKT independent actions of Pi3′-kinase would be a very 
interesting phenomenon to investigate in a future study.
In conclusion, we have demonstrated here that the 
combination of a MEK1/2 inhibitor with a PI3′-kinase 
inhibitor in the context of thyroid cancer is a valid 
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approach that could relatively easy be translated into 
clinical practice. The advances in management of MEK 
inhibitors could allow such treatment to be realistically 
considered for patients, avoiding the toxic side effects 
(of current MEK inhibitors). The most interesting part 
is really the fact that MEK inhibition induces a kind of 
“re- diferentiation” of the thyroid, finally opening the door 
for new clinical managements of ATC cancer patients, a 
disease where the standard treatment of care has not 
changed much in the last 40 years.
MATERIALS AND METHODS
Chemicals
Unless specified otherwise, chemicals were purchased 
from Sigma-Aldrich Switzerland. MEK and Pi3′-kinase 
inhibitors, PD-325901 and GDC-0941 respectively, have 
been purchased from AbMole Bioscience Hong-Kong.
Animals
Compound mice were obtained by combining 
the following alleles: BrafCA [40], Pik3caLat [41] and 
Thyroglobulin-CreERT2 [42]. Mutations were induced by 
5 consecutive daily injections of 1 mg tamoxifen IP. Mice 
were kept in isolated ventilated cages, fed ad libitum in a 
12/12 h cycle of light and dark. Mice were kept, treated 
and euthanized according to the Swiss federal guidelines. 
The experimental protocol was approved by the Bernese 
cantonal ethical commission for animal experimentation 
(Licence number: BE120/13).
Cell lines
8505c cells have a BRAFV600E mutation in addition 
to p53 and CDKN2A alterations. Cells were purchased at 
the Public Health England repository (Culture Collections, 
Salisbury-UK) and cultured in RPMI 10% Fetal Bovine 
Serum (FBS), 2 mM L-glutamine, 1% Non-Essential Amino 
Acids (NEAA) and 1% Penicillin/Streptomycin (P/S). OCUT-
2 carries concomitant BRAFV600E and PIK3CAH1047R mutations 
which was donated by Prof. James Fagin (Memorial Sloan 
Kettering Cancer Center) validated by Single-nucleotide 
polymorphism (SNP) and cultured in DMEM medium 
supplemented with 10% FBS, 2 mM L-glutamine, 1% NEAA 
and 1% P/S. SW1736 is a BRAFV600E/PIK3CAWT cell line 
purchased at the Cell Line Service (CLS, Eppelheim-DE) and 
cultured in RPMI 10% FBS, 2 mM L-glutamine and 1% P/S. 
All cell lines were cultured for a maximum of 40 passages or 
6 months; whichever limit was reached first.
Synergy calculation method
Five-fold serial working dilutions were prepared 
in RPMI-1640 medium. PD-325901 and GDC-0941 
were used respectively at the following concentrations 
(100 nM, 20 nM, 4 nM, 0.8 nM, 0.16 nM) and (2 µM, 
400 nM, 80 nM, 16 nM, 3.2 nM) in SW1736 and OCUT-
2 cell lines. In 8505c the final concentrations used were 
(200 nM, 40 nM, 8 nM, 1.6 nM, 0.32 nM) for PD-325901 
and (3 µM, 600 nM, 120 nM, 24 nM, 4.8 nM) for GDC-
0941. These concentrations represent approximately (10, 
2, 0.4, 0.08 and 0.016) times fold of the calculated IG50 
for each drug in each cell line. Cells were incubated 72 h 
then formalin-fixed and stained with crystal violet. Crystal 
violet was recovered in Sodium Dodecyl Sulphate 1%. 
Optical density at 550 nm was measured after lysis and 
normalized to the untreated cells. Curves of percentage 
of inhibition as a function of IG50 equivalents were 
obtained. This constant ratio approach allows to calculate 
the combination index (CI) values. CI = (D)1/(Dx)1 + (D)2/
(Dx)2 [26].
At 50% inhibition level, (Dx)1 and (Dx)2 are the 
concentrations of PD-325901 and GDC-0941, respectively 
that induce alone a 50% inhibition of cell growth; (D)1 
and (D)2 are concentrations of PD-325901 and GDC-0941 
in combination, which also inhibits cell growth by 50% 
(D)1/(Dx)1 reflect how much Drug 2 potentiate the affect of 
Drug 1 and (D)2/(Dx)2 reflect how much Drug 1 potentiate 
Drug 2 in combination. When the 2 drugs potentiate each 
other (Synergy) each one lowers the concentration of the 
other which is necessary to reproduce the same effect as 
a single agent.
The combination index was calculated for each 
percentage of inhibition or fraction affected (Fa). 
Synergism or antagonism was calculated on the basis of 
the multiple drug-effect equation and evaluated by the CI, 
where CI < 1, CI = 1, and CI > 1 indicate respectively 
synergism, additivity and antagonism using Compusyn 2.0 
software based on the Chou and Talalay method.
Cell cycle analysis by propidium iodide (PI) 
staining
After 24 h, the medium was centrifuged for 5′ at 
300 g to recover the floating cells. Attached cells were 
trypsinized (Trypsin 0.05%) and recovered with medium. 
After 5′ of centrifugation at 300 g, the pellets were 
re-suspended in PBS, and counted using a Neubauer 
chamber. Then attached cells were pooled with the floating 
cells and centrifuged for 5′ at 300 g. Cells were then 
re-suspended in cold PBS at 1 million cells/ml. Then, 
cells were centrifuged for 5′ at 300 g and the pellet was 
re-suspended in 0.3 ml cold PBS /million cells. Then 
0.7 ml cold ethanol 70% per million cells was added 
drop wise while vortexing gently. The suspensions were 
aliquoted in 1 ml aliquots and left over night at 4°C.
The tubes were centrifuged 10′ at 1,000 g at 4°C 
and the supernatants were decanted. Pellets were washed 
once with 1 ml cold PBS 1x and then centrifuged 10′ at 
1,000 g at 4°C. Cells pellets were re-suspended in 250 μl 
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of cold PBS 1x and 5 μl of 10 mg/ml RNase A was added. 
After an incubation of 30′ at 37°C, 10 μl of PI solution 
(40 μg/ ml) was added, the cells were then incubated 10′ 
at room temperature in the dark and then analyzed using 
FACS (BD FACScan equipped with a Cytek solid state 
laser, and FCS Express De Novo software).
AnnexinV/Propidium iodide staining for flow 
cytometry analysis
Cells were treated with PD-325901 and/or GDC-
0941 at 100 nM and 1 µM concentration respectively 
for 24 h or 48 h. Floating cells were centrifuged at 1,000 
g for 10′. Attached cells were washed with PBS and 
trypsinized before re-suspending them in the appropriate 
media. Cells suspensions were centrifuged at 300 g for 
10′, re-suspended in cold PBS before a second round of 
centrifugation at 300 g for 10′. The fractions of floating 
cells and attached cells were pooled in 1X annexinV 
binding buffer and re-suspended. Cells were counted 
and 100 µl of cell suspension containing 105 cells was 
transferred to a 5 ml culture tubes. BD Pharmingen FITC 
annexinV Apoptosis Detection Kit I (BD Biosciences) was 
used for the staining. 5 µl of FITC annexinV and 10 µl 
of PI were added to the suspension, gently vortexed and 
incubated for 15′ at room temperature in the dark before 
measuring by flow cytometry within 1 h.
Total protein preparation from cells
After 24 h of treatment, both floating and attached 
cells were recovered. They were then centrifuged for 5′ at 
350 g at 4°C and washed twice with 10 ml cold PBS and 
re-suspended in 1 ml cold PBS. Cells were then pelleted at 
500 g and lysed in RIPA buffer with Halt™ Protease and 
Phosphatase Inhibitor Cocktail (Pierce, ThermoFischer 
Scientific). The lysates were incubated 30′ on ice and then 
centrifuged for 15′ at 16,000 g at 4°C. Supernatants were 
recovered, and protein concentrations were quantified by 
the Bradford method (Pierce, ThermoFischer Scientific, 
BCA Protein Assay Kit).
Lysates were prepared at 1-4 µg/µl in sample buffer 
(5x; 1.47 M sucrose, 10% SDS, 5 mM EDTA, 300 mM 
Tris pH 8.8, 0.25% Bromophenol blue, and 130 mM 
dithiothreitol) and the proteins were run on TGX precast 
4-20% gels (BioRad, Switzerland), transferred onto Trans-
Blot transfer pack nitrocellulose (BioRad, Switzerland), 
and analyzed by western blotting.
Nuclear extract preparation
After 24 h of treatment, cells were washed twice 
with cold PBS 1x. Then they were scrapped in PBS 
and centrifuged for 5′ at 350 g at 4°C. The pellets were 
re-suspended in 500 µl of hypotonic buffer (20 mM Tris 
pH 7.4, 10 mM NaCl, 3 mM MgCl2) and incubated for 
15′ on ice. Then, 25 µl of 10% IGEPAL® CA-630 was 
added to each tube and after vortexing for 10 s at highest 
speed, they were centrifuged for 10′ at 1,000 g at 4°C. 
The pellets were re-suspended in 40-80 µl of RIPA/
Halt™ (Halt cocktail, ThermoFischer Scientific). Finally, 
they were cleared at 16,000 g at 4°C for 30′. The protein 
concentrations and the preparation of the lysates were 
performed as described above.
Drug treatments and ultrasound imaging
Mice were treated by oral gavage with 5 mg/kg of PD-
325901 or 50 mg/kg of GDC-0941, or the combination of 
both, formulated in 5% hydroxpropyl methylcellulose 6 days 
per week. Mice were anesthetized with 5 μl/g body weight of 
a mixture of 0.1 mg/ml Dorbene, 0.5 mg/ml Dormicum and 
5 μg/ml Fentanyl in 0.9% NaCl injected intraperitoneally. 
The fur around the neck was epilated with Veet® hair removal 
cream. Pictures were acquired with an ESAOTE MyLab Five 
ultrasound machine using a LA455 Probe (18 MHz) from 
Siemens. After imaging, mice were taken out of anesthesia 
with 10 μl/g body weight of a mixture of 0.25 mg/ml Alzan, 
5 μg/ml Flumazenil and 20 μg/ml Naloxon in 0.9% NaCl 
injected sub-cutaneously. Images were analyzed using the 
ImageJ software. Tumor burden was assayed as the surface 
of the biggest thyroid section observed and normalized to the 
size at the beginning of the experiment.
Immunofluorescence
Mice were anesthetized using 10 µl/g of bodyweight 
of a Ketamin/Xylazin mixture (10 mg/ml and 1.6 mg/ ml 
respectively) injected intraperitoneally. Thyroids were 
dissected and washed with ice cold PBS. Tissues were fixed 
overnight in 10% neutral buffered formalin solution (Sigma). 
After paraffin embedding, 5 μm sections were prepared. 
Sections were rehydrated and targets were retrieved in 
TEG buffer (10 mM Tris and 0.5 mM EGTA). Sections 
were blocked three times 10′ in a buffer of 1% BSA, 0.2% 
gelatin, and 0.05% Saponin in PBS. Antibodies were 
diluted in 0.1% BSA and 0.3% Triton X-100 in PBS to the 
following concentrations: KI67 (Abcam-16667 1:300), CC3 
(CST-9664S 1:300), CK19 (TROMA-III DSHB 1:300), 
Galectin-3 (Abcam-53082 1:300). Primary antibodies were 
incubated over night at 4°C. The slides were washed three 
times with 0.1% BSA, 0.2% gelatin and 0.05% Saponin in 
PBS. The secondary antibody was goat anti Rabbit 488 Life 
Technologies A-11034 1:500. DAPI Sigma 32670 was used 
at a final concentration of 5 µg/µl. Secondary antibodies 
were incubated 1 h at room temperature.
Microscopy
Immunofluorescence and histology pictures were 
scanned with a Panoramic Midi Scanner (Sysmex/3DHISTECH 
Switzerland/Hungary). Analysis and quantification was 




For histological analysis, tissue samples were 
processed as described above and stained with Hematoxylin 
(Sigma GHS132) and Eosin (HT110132) following 
standard protocols. 
Antibodies for western blots
Primary antibodies (dilution and catalogue number; 
all CST antibodies were purchased from Bioconcept AG, 
Allschwil, Switzerland): p44/42 MAPK (Erk1/2) (1:5000; 
CST-9107), phospho-p44/42 MAPK (Erk1/2) (1:2000; 
CST-4370), AKT (pan) (1:2000; CST-2920), phospho-
AKT (Ser473) (1:2000; CST-4060), Phospho-4E-BP1 
(Thr37/46) (1:2000; CST-2855), phospho-S6 (Ser240/244) 
(1:6000; CST-4858), XIAP (1:1000, CST-2042), CC3 
(1:2000; CST-9664), gamma H2A.X (Phospho S139) 
(1:1000; Abcam-26350), AIF (1:2000, Abcam-32516), 
Survivin (1:500; Santa Cruz 17779). 
Secondary antibodies were from Li-Cor Biosciences, 
Bad Homburg Germany: IRDye 680RD Goat anti-Rabbit 
IgG (H + L) (1:10,000, 926-68071), IRDye 800CW Goat 
anti-Mouse IgG (H + L) (1:10,000, 926-32210).
Real time PCR
Total RNAs were purified with the QIAzol 
reagent from Qiagen according to the manufacturer’s 
instructions. For RT-PCR experiments, total RNA (500 
ng) was subjected to reverse transcription to produce 
cDNA using Oligo(dT)12-18 Primer and the Super 
Script II Reverse Transcriptase (Invitrogen®) then run on 
ViiA™ 7 Real-Time PCR System (Applied Biosystems, 
Life Technologies) using the TaqMan® gene expression 
Master Mix and primers from Applied Biosystems. Actin 
was used as housekeeping gene and mean CT Values and 
standard deviations are used in the ΔΔCT calculation 
(comparative CT method). Each sample was run in 
triplicate. The primers used were purchased from Applied 
Biosystems, Life Technologies: Nis (Mm01351811_m1), 
Tg (Mm01200340_m1), Ttf1 (Mm00657018_m1), Pax8 
(Mm00440623_m1), Tpo (Mm00456355_m1), Tshr 
(Mm00442027_m1), and Actb (4352341E).
Statistical methods
Two-way ANOVA test with Tukey as post hoc 
test were used to compare tumor burdens between the 4 
treatments at for different time points (Figure 4). One-way 
ANOVA test with Dunnett as post hoc test was used for 
the quantification of pERK and pAKT western blots at 
9 weeks (Figure 5) and for the FACS analysis apoptosis 
(Figure 2). Otherwise, a Student’s ttest was used to 
compare pERK and pAKT in thyroids of mice treated 
with a single dose GDC (Figure 5). One-way ANOVA test 
and Tukey test were used in all other statistical analysis 
(Cell cycle Figure 1; Immuno stainings Figure 7; qPCR 
Figure 8).
All statistical analyses were performed using the 
software Graphpad Prism. Significance in the figures is 
displayed using stars with one star meaning a resulting 
p-value of smaller than or equal to 0.05. Two stars means 
a p-value of smaller than or equal to 0.01. Three stars 
stands for a p-value of smaller than or equal to 0.001. If a 
p-value was greater than 0.05 the difference between the 
two concerning groups was regarded as not significant.
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